ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Clinical Depression

AJ Russo[1]*, Albert Mensah[2] and Judith Bowman[2]

[1]*Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA*
[2]*Mensah Research Institute, Warrenville, Il, USA*

***Corresponding Author:** AJ Russo, Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.

Received: December 16, 2024; **Published:** January 29, 2025

Abstract

Clinical depression is a multifaceted disorder characterized by various neurobiological alterations, including dysregulation of intracellular signaling pathways. Neurotrophic growth factors such as Brain-Derived Neurotrophic Factor (BDNF), Glial Cell Line-Derived Neurotrophic Factor (GDNF), and Insulin-Like Growth Factor (IGF). These factors are pivotal in neurogenesis, neuronal survival, and synaptic plasticity, all crucial for maintaining emotional and cognitive functions. Various receptor systems, including serotonin receptors, dopamine receptors, GABA receptors, and purinergic receptors, play critical roles in the pathophysiology of depression. The mitogen-activated protein kinase (MAPK) pathway, particularly the extracellular signal-regulated kinase (ERK) pathway, has been extensively studied for its involvement in mood regulation and the efficacy of antidepressant treatments. The cyclic adenosine monophosphate response element-binding protein (CREB) is a well-established transcription factor implicated in the pathophysiology of depression. Collectively, these pathway elements are implicated in the etiology of clinical depression.

Keywords: *Brain-Derived Neurotrophic Factor (BDNF); Glial Cell Line-Derived Neurotrophic Factor (GDNF); Insulin-Like Growth Factor (IGF)*

Growth factors associated with clinical depression

The intricate relationship between growth factors and clinical depression has garnered significant attention in recent years, particularly in the context of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF), Glial Cell Line-Derived Neurotrophic Factor (GDNF), and Insulin-Like Growth Factor (IGF). These factors are pivotal in neurogenesis, neuronal survival, and synaptic plasticity, all of which are crucial for maintaining emotional and cognitive functions. The neurotrophic hypothesis of depression posits that a deficiency in these neurotrophic factors contributes to the pathophysiology of depression, leading to decreased neuroplasticity and neuronal atrophy in brain regions associated with mood regulation, such as the hippocampus and prefrontal cortex [1-3].

BDNF, in particular, has been extensively studied as a key player in the neurotrophic hypothesis. Research indicates that stress and depressive states are associated with decreased BDNF expression, which in turn leads to impaired neurogenesis and increased neuronal apoptosis [4-6]. For instance, studies have shown that chronic stress results in reduced BDNF levels, which correlates with the atrophy of neurons in the hippocampus, a brain region critical for mood regulation and memory [4-6]. Furthermore, antidepressant treatments have

been shown to reverse these deficits by increasing BDNF levels, thereby promoting neuroplasticity and neuronal survival [2,7,8]. This relationship underscores the importance of BDNF as both a biomarker and a therapeutic target in depression.

In addition to BDNF, other neurotrophic factors such as GDNF and IGF have also been implicated in the pathophysiology of depression. GDNF is known to support the survival of dopaminergic neurons and has been shown to exert neuroprotective effects in various models of neurodegeneration [9,10]. Similarly, IGF has been linked to neuroplasticity and cognitive function, with evidence suggesting that alterations in IGF signaling may contribute to the development of depressive symptoms [10,11]. The interplay between these neurotrophic factors and their receptors is crucial for maintaining neuronal health and function, and disruptions in this signaling cascade may lead to the onset of depressive disorders [10,11].

Moreover, the role of neurotrophic factors extends beyond their neuroprotective properties; they are also involved in the modulation of neurotransmitter systems that are often dysregulated in depression. For example, BDNF signaling has been shown to influence serotonin and dopamine pathways, which are critical for mood regulation [2,3,12]. The interaction between neurotrophic factors and neurotransmitter systems suggests a complex network of signaling pathways that contribute to the development and maintenance of depressive symptoms. This complexity highlights the need for a multifaceted approach to understanding and treating depression, as targeting a single pathway may not be sufficient for all patients.

Recent advancements in therapeutic strategies have also focused on enhancing neurotrophic factor signaling as a means to alleviate depressive symptoms. For instance, ketamine, an NMDA receptor antagonist, has been shown to rapidly increase BDNF levels and promote synaptic plasticity, offering a novel mechanism for treating treatment-resistant depression [8,12]. Additionally, phytochemicals and other natural compounds that enhance neurotrophic factor expression are being explored as potential adjunctive therapies for depression [9,13]. These emerging treatments underscore the importance of neurotrophic factors in developing innovative therapeutic strategies for managing depression.

The relationship between neurotrophic factors and depression is further complicated by genetic and environmental factors that can influence their expression and function. Genetic polymorphisms in the BDNF gene have been associated with an increased risk of developing depression, suggesting that individual differences in neurotrophic factor signaling may contribute to the heterogeneity of depressive disorders [14-16]. Environmental stressors, such as trauma and chronic stress, can also lead to alterations in neurotrophic factor levels, thereby exacerbating the risk of depression [11,16]. Understanding these interactions is crucial for developing personalized treatment approaches that consider both biological and environmental factors.

In summary, the evidence supporting the role of neurotrophic factors in the pathophysiology of clinical depression is robust and multifaceted. BDNF, GDNF, and IGF are central to maintaining neuronal health and function, and their dysregulation is closely linked to the development of depressive symptoms. The neurotrophic hypothesis provides a valuable framework for understanding the biological underpinnings of depression and highlights the potential for targeting neurotrophic factor signaling in therapeutic interventions. Future research should continue to explore the complex interactions between neurotrophic factors, neurotransmitter systems, and environmental influences to develop more effective strategies for preventing and treating depression.

Cell receptors associated with clinical depression

The exploration of cell receptors associated with clinical depression has become a focal point in understanding the neurobiological underpinnings of this complex disorder. Various receptor systems, including serotonin receptors, dopamine receptors, GABA receptors, and purinergic receptors, play critical roles in the pathophysiology of depression. This multifaceted involvement underscores the necessity of a comprehensive approach to treatment that targets these receptors to restore neurochemical balance.

Serotonin receptors, particularly the 5-HT receptor subtypes, have been extensively studied in relation to depression. The 5-HT1B receptor, for instance, is implicated in the modulation of emotional memory and has been shown to influence the efficacy of antidepressants [17,18]. Activation of this receptor can enhance serotonergic signaling, which is crucial for mood regulation. Additionally, the 5-HT3 receptor has been identified as playing a complex role in mood disorders, as it is involved in the regulation of neurotransmitter systems relevant to depression [19]. The intricate interplay between these serotonin receptors and their respective signaling pathways highlights the importance of serotonin in the etiology of depression and the therapeutic potential of targeting these receptors.

Dopamine receptors, particularly the D2 and D3 subtypes, are also significantly associated with mood disorders. Research indicates that D3 receptors in the nucleus accumbens are downregulated in response to stress, and this downregulation can be reversed with antidepressant treatment [20]. This suggests that dopamine signaling is not only crucial for reward processing but also plays a role in the emotional dysregulation observed in depression. Furthermore, the interaction between dopamine and serotonin systems is essential for understanding the neurobiological mechanisms underlying depression, as both neurotransmitter systems are interrelated and influence each other's activity [21].

GABAergic signaling, mediated by GABA receptors, has emerged as a critical factor in the pathophysiology of depression. Studies have shown that individuals with major depressive disorder (MDD) exhibit reduced levels of GABA, an inhibitory neurotransmitter, leading to increased neuronal excitability and mood dysregulation [22,23]. The GABA_A receptor, in particular, has been implicated in the therapeutic effects of various antidepressants, as enhancing GABAergic transmission can alleviate depressive symptoms [23]. The GABAergic deficit hypothesis posits that alterations in GABA receptor function contribute to the development of depressive disorders, emphasizing the need for treatments that target this receptor system [22].

Purinergic receptors, specifically the P2X7 receptor, have gained attention in recent years for their role in mood disorders. The P2X7 receptor is activated by adenosine triphosphate (ATP) and is involved in mediating inflammatory responses in the central nervous system [24,25]. Dysregulation of purinergic signaling has been linked to the pathophysiology of depression, with evidence suggesting that ATP-mediated signaling through P2X7 receptors may influence synaptic plasticity and neuronal survival [24,26]. The potential of targeting purinergic receptors for therapeutic interventions in depression is an exciting area of research, as it may provide novel strategies for treatment-resistant cases.

The involvement of epigenetic factors in receptor expression and function further complicates the landscape of depression. Chronic stress has been shown to induce epigenetic changes that affect dopamine receptor signaling, particularly the D2 receptor, which may contribute to the onset of depressive symptoms [27]. Understanding how environmental factors influence receptor expression through epigenetic mechanisms could lead to innovative approaches for preventing and treating depression. Moreover, the role of estrogen receptors in depression, particularly in women, has been highlighted in recent studies. Variations in estrogen receptor genes have been associated with an increased risk of developing depression, suggesting that hormonal fluctuations may influence receptor-mediated signaling pathways involved in mood regulation [28]. This connection underscores the importance of considering gender differences in the pathophysiology of depression and the potential for hormone-based therapies.

In summary, the intricate network of cell receptors involved in clinical depression encompasses serotonin, dopamine, GABA, and purinergic systems, each contributing to the neurobiological mechanisms underlying this disorder. The interplay between these receptors and their signaling pathways highlights the complexity of depression and the need for multifaceted treatment approaches. Future research should continue to explore the interactions between these receptor systems, the impact of epigenetic factors, and the potential for novel therapeutic targets to improve outcomes for individuals suffering from depression.

Intracellular kinases associated with clinical depression

Clinical depression is a multifaceted disorder characterized by various neurobiological alterations, including dysregulation of intracellular signaling pathways. A significant body of research has identified several intracellular kinases that play critical roles in the pathophysiology of depression. Among these, the mitogen-activated protein kinase (MAPK) pathway, particularly the extracellular signal-regulated kinase (ERK) pathway, has been extensively studied for its involvement in mood regulation and the efficacy of antidepressant treatments.

The ERK1/2 signaling pathway is a crucial mediator of neurotrophic factor signaling, particularly brain-derived neurotrophic factor (BDNF), which is essential for neuronal survival, growth, and synaptic plasticity. Studies have demonstrated that the activation of ERK1/2 is necessary for the antidepressant-like effects observed in various animal models of depression [29,30]. For instance, the phosphorylation of ERK1/2 has been linked to the neurogenic effects of antidepressants, suggesting that enhancing this signaling pathway may contribute to the therapeutic effects of these medications [31]. Furthermore, alterations in ERK signaling have been observed in the brains of individuals with major depressive disorder, indicating a potential biomarker for the disease [32].

In addition to ERK1/2, glycogen synthase kinase 3 beta (GSK3β) is another critical kinase implicated in the pathophysiology of depression. GSK3β is involved in various cellular processes, including metabolism, cell differentiation, and apoptosis. Dysregulation of GSK3β activity has been associated with mood disorders, as its inhibition has been shown to produce antidepressant-like effects in preclinical models [33,34]. The interplay between GSK3β and the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is particularly noteworthy, as AKT activation leads to the inactivation of GSK3β, thereby promoting neuroprotective effects and enhancing mood [33,34].

Moreover, the role of the mTOR (mechanistic target of rapamycin) pathway in depression has garnered increasing attention. mTOR signaling is involved in protein synthesis and synaptic plasticity, and its dysregulation has been implicated in the development of depressive symptoms. Research indicates that mTOR activation may mediate the effects of various antidepressants, highlighting its potential as a therapeutic target for depression [35]. The interplay between mTOR and other signaling pathways, such as the MAPK and PI3K pathways, further underscores the complexity of intracellular signaling in mood regulation [36].

Neuroinflammation has also emerged as a critical factor in the pathophysiology of depression, with intracellular signaling pathways mediating the effects of inflammatory cytokines on mood. For instance, the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway in response to pro-inflammatory cytokines can lead to alterations in neurotransmitter systems and neuroplasticity, contributing to depressive symptoms [37,38]. The interaction between inflammatory signaling and intracellular kinases, such as ERK and GSK3β, suggests a multifactorial approach to understanding the neurobiological underpinnings of depression [37].

Furthermore, recent studies have highlighted the significance of non-receptor tyrosine kinases (nRTKs) in the context of depression. These kinases, including focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2), are involved in cell signaling pathways that regulate neuronal plasticity and stress responses. Their dysregulation has been linked to the development of depression-like behaviors in animal models, indicating their potential role in mood disorders [39,40]. The integration of nRTK signaling with other pathways, such as the MAPK and PI3K pathways, illustrates the complexity of intracellular signaling networks in the context of depression [39].

In summary, intracellular kinases, particularly those involved in the MAPK, PI3K/AKT, and mTOR pathways, play pivotal roles in the pathophysiology of clinical depression. The dysregulation of these signaling pathways can lead to impaired neuroplasticity, altered neurotransmitter systems, and increased vulnerability to stress, all of which contribute to the development and persistence of depressive symptoms. Future research aimed at elucidating the intricate interactions between these signaling pathways may provide valuable insights into novel therapeutic strategies for treating depression.

Transcription factors associated with clinical depression

Clinical depression is a multifaceted disorder characterized by a complex interplay of genetic, environmental, and neurobiological factors. One of the critical components in understanding the pathophysiology of depression is the role of transcription factors, which are proteins that regulate gene expression and can significantly influence neuronal function and mood regulation. This synthesis will explore various transcription factors associated with clinical depression, drawing on a range of studies that highlight their roles in the disorder.

The cyclic adenosine monophosphate response element-binding protein (CREB) is a well-established transcription factor implicated in the pathophysiology of depression. CREB is involved in the regulation of brain-derived neurotrophic factor (BDNF), which is crucial for neuronal survival and plasticity. Studies have shown that alterations in CREB signaling can lead to decreased BDNF expression, contributing to the development of depressive symptoms [41,42]. Furthermore, the phosphorylation of CREB in response to estrogen has been linked to affective behaviors, suggesting that hormonal fluctuations can modulate CREB activity and, consequently, mood [41].

Another significant transcription factor in the context of depression is nuclear factor kappa B (NF-κB). This factor is activated by pro-inflammatory cytokines, which are often elevated in individuals with depression. Research indicates that NF-κB mediates stress-induced neuroinflammation, leading to impaired neurogenesis and exacerbation of depressive behaviors [43,44]. The interplay between NF-κB and cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) underscores the role of inflammation in the etiology of depression [45,46]. Elevated levels of these cytokines have been associated with reduced hippocampal volume, a common finding in depressed patients [47].

The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) has emerged as a critical player in the oxidative stress response and inflammation, both of which are implicated in depression. Nrf2 regulates the expression of antioxidant genes and has been shown to ameliorate depression-like behaviors in animal models by promoting neuroprotection [48,49]. Its activation can counteract the detrimental effects of oxidative stress and inflammation, suggesting potential therapeutic avenues for targeting Nrf2 in depression treatment [50].

Additionally, the early growth response (EGR) family of transcription factors, particularly EGR-1, has been linked to mood regulation. EGR-1 is rapidly induced by various stimuli, including stress and neurotrophic factors, and is involved in synaptic plasticity and memory formation [51,52]. Dysregulation of EGR-1 has been observed in models of depression, indicating its potential role in the neurobiological underpinnings of the disorder [51,52].

The role of the transcription factor TCF7L2 in depression is also gaining attention. Recent studies suggest that TCF7L2 may regulate the effects of antidepressants on hippocampal astrocytes, highlighting its involvement in the neurobiological mechanisms of mood disorders [53]. This underscores the importance of exploring how various transcription factors interact with pharmacological treatments to enhance therapeutic outcomes.

Moreover, the transcription factor AP-1, which is activated by the mitogen-activated protein kinase (MAPK) signaling pathway, has been implicated in the regulation of gene expression changes associated with chronic stress and depression [54,55]. The activation of AP-1 can lead to the expression of pro-inflammatory cytokines, further linking inflammation to the transcriptional landscape of depression [54,55].

In the context of epigenetics, histone deacetylases (HDACs) have been shown to play a role in the transcriptional regulation of genes associated with mood disorders. Inhibition of HDACs can lead to increased expression of neurotrophic factors and improved mood-related behaviors in animal models, suggesting that epigenetic modifications are crucial in the pathophysiology of depression [54,55]. This highlights the potential for HDAC inhibitors as novel therapeutic agents in treating depression.

The interplay between transcription factors and neurotrophic factors such as BDNF is particularly noteworthy. BDNF signaling through its receptor TrkB is essential for neuronal survival and plasticity, and its dysregulation has been implicated in the development of depression [56,57]. Transcription factors like CREB and NF-κB influence BDNF expression, thus affecting mood and cognitive functions [56,58].

Furthermore, the role of microRNAs in regulating transcription factors and their downstream targets has been increasingly recognized in the context of depression. MicroRNA-124, for example, has been shown to suppress the expression of BDNF, linking microRNA regulation to the transcriptional control of mood-related genes [59,60]. This suggests that targeting microRNAs could provide a novel approach to modulating transcriptional responses in depression.

Conclusion

In summary, transcription factors play a pivotal role in the pathophysiology of clinical depression through their regulation of gene expression, interaction with neurotrophic factors, and involvement in inflammatory processes. The intricate network of transcriptional regulation highlights the complexity of depression and the need for multifaceted therapeutic strategies that target these molecular pathways. Future research should continue to elucidate the specific roles of various transcription factors and their potential as therapeutic targets in the treatment of depression.

Bibliography

1. Ċastrén E and Monteggia LM. "Brain-derived neurotrophic factor signaling in depression and antidepressant action". *Biological Psychiatry* 90.2 (2021): 128-136.

2. Dwivedi YK. "Involvement of brain-derived neurotrophic factor in late-life depression". *The American Journal of Geriatric Psychiatry* 21.5 (2013): 433-449.

3. Phillips C. "Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection". *Neural Plasticity* (2017): 7260130.

4. Bliźniewska-Kowalska K., *et al*. "Expression of selected genes involved in neurogenesis in the etiopathogenesis of depressive disorders". *Journal of Personalized Medicine* 11.3 (2021): 168.

5. Molendijk ML., *et al*. "Serum bdnf concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (n=9484)". *Molecular Psychiatry* 19.7 (2013): 791-800.

6. Molendijk ML., *et al*. "Serum levels of brain-derived neurotrophic factor in major depressive disorder: state–trait issues, clinical features and pharmacological treatment". *Molecular Psychiatry* 16.11 (2010): 1088-1095.

7. Jiang B., *et al*. "Skf83959 produces antidepressant effects in a chronic social defeat stress model of depression through bdnf-trkb pathway". *International Journal of Neuropsychopharmacology* 18.6 (2015).

8. Borsellino P., *et al*. "Ketamine and the disinhibition hypothesis: neurotrophic factor-mediated treatment of depression". *Pharmaceuticals* 16.5 (2023): 742.

9. Wang H., *et al*. "Neurotrophic basis to the pathogenesis of depression and phytotherapy". *Frontiers in Pharmacology* 14 (2023).

10. Patel RM and Rana DG. "Role of insulin-like growth factor in depression: a review". *International Research Journal of Pharmacy* 12.3 (2021): 6-10.

11. Ċastrén E. "Neurotrophins and psychiatric disorders". *Handbook of Experimental Pharmacology* (2014): 461-479.

12. Duman RS and Voleti B. "Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents". *Trends in Neurosciences* 35.1 (2012): 47-56.

13. Zhu Y., *et al*. "Elaphuri davidiani cornu improves depressive-like behavior in mice and increases neurotrophic factor expression in mouse primary astrocytes via camp and erk-dependent pathways". *Frontiers in Pharmacology* 11 (2020).

14. Buttenschøn HN., *et al*. "Increased serum levels of sortilin are associated with depression and correlated with bdnf and vegf". *Translational Psychiatry* 5.11 (2015): e677-e677.

15. Chiou Y and Huang T. "Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode major depressive disorder: effects of antidepressants". *International Journal of Neuropsychopharmacology* (2016): pyw096.

16. Markov D., *et al*. "The melanocortin system: a promising target for the development of new antidepressant drugs". *International Journal of Molecular Sciences* 24.7 (2023): 6664.

17. Eriksson T., *et al*. "Bidirectional regulation of emotional memory by 5-ht1b receptors involves hippocampal p11". *Molecular Psychiatry* 18.10 (2012): 1096-1105.

18. Svenningsson P., *et al*. "P11 and its role in depression and therapeutic responses to antidepressants". *Nature Reviews Neuroscience* 14.10 (2013): 673-680.

19. Bétry C., *et al*. "Role of 5-ht3 receptors in the antidepressant response". *Pharmaceuticals* 4.4 (2011): 603-629.

20. Roméo B., *et al*. "Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety". *Journal of Psychopharmacology* 32.4 (2018): 385-396.

21. Anyanwu GE., *et al*. "Putative role of monoaminergic systems in antidepressant and anxiolytic effects of naringin in mice: an interaction study with receptor antagonists". *Journal of Pharmaceutical Research International* (2021): 661-676.

22. Lüscher B., *et al*. "The gabaergic deficit hypothesis of major depressive disorder". *Molecular Psychiatry* 16.4 (2010): 383-406.

23. Cutler A., *et al*. "Understanding the mechanism of action and clinical effects of neuroactive steroids and gabaergic compounds in major depressive disorder". *Translational Psychiatry* 13.1 (2023).

24. Ribeiro D., *et al*. "P2x7 receptor signaling in stress and depression". *International Journal of Molecular Sciences* 20.11 (2019): 2778.

25. Wei L., *et al*. "Atp-activated p2x7 receptor in the pathophysiology of mood disorders and as an emerging target for the development of novel antidepressant therapeutics". *Neuroscience and Biobehavioral Reviews* 87 (2018): 192-205.

26. Bartoli F., *et al*. "Purinergic signaling and related biomarkers in depression". *Brain Sciences* 10.3 (2020): 160.

27. Moriam S and Sobhani ME. "Epigenetic effect of chronic stress on dopamine signaling and depression". *Genetics and Epigenetics* 5 (2013).

28. Ryan J and Ancelin M. "Polymorphisms of estrogen receptors and risk of depression". *Drugs* 72.13 (2012): 1725-1738.

29. Jiang B., *et al*. "Antidepressant-like effects of ginsenoside rg1 are due to activation of the bdnf signalling pathway and neurogenesis in the hippocampus". *British Journal of Pharmacology* 166.6 (2012): 1872-1887.

30. Wang L., *et al*. "The extracellular signal-regulated kinase pathway may play an important role in mediating antidepressant-stimulated hippocampus neurogenesis in depression". *Medical Hypotheses* 79.1 (2012): 87-91.

31. Tripp A., *et al*. "Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder". *American Journal of Psychiatry* 169.11 (2012): 1194-1202.

32. Orrico-Sánchez A., *et al*. "Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression". *Molecular Psychiatry* 25.6 (2019): 1245-1259.

33. Yan T., *et al*. "Antidepressant-like effects and cognitive enhancement of schisandra chinensis in chronic unpredictable mild stress mice and its related mechanism". *Scientific Reports* 7.1 (2017).

34. Crofton E., *et al*. "Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell". *Neuropharmacology* 117 (2017): 49-60.

35. Orrico-Sanchez A., *et al*. "Organic cation transporter 2 contributes to ssri antidepressant efficacy by controlling tryptophan availability in the brain". *Translational Psychiatry* 13.1 (2023).

36. Christensen T., *et al*. "Molecular profiling of the lateral habenula in a rat model of depression". *PLoS ONE* 8.12 (2013): e80666.

37. Bansal Y and Kuhad A. "Mitochondrial dysfunction in depression". *Current Neuropharmacology* 14.6 (2016): 610-618.

38. Đurić V and Duman RS. "Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes". *Cellular and Molecular Life Sciences* 70.1 (2012): 39-53.

39. Wang J., *et al*. "Roles of non-receptor tyrosine kinases in pathogenesis and treatment of depression". *Journal of Integrative Neuroscience* 21.1 (2022): 025.

40. Hsin H., *et al*. "Proline-rich tyrosine kinase 2 regulates hippocampal long-term depression". *The Journal of Neuroscience* 30.36 (2010): 11983-11993.

41. Hu Y., *et al*. "Hippocampal nitric oxide contributes to sex difference in affective behaviors". *Proceedings of the National Academy of Sciences* 109.35 (2012): 14224-14229.

42. Davis RL. "Understanding depression: the hippocampus might hold the answer in a creb-regulated transcription coactivator". *Journal of Neurochemistry* 149.1 (2019): 9-11.

43. Koo JW., *et al*. "Nuclear factor-κb is a critical mediator of stress-impaired neurogenesis and depressive behavior". *Proceedings of the National Academy of Sciences* 107.6 (2010): 2669-2674.

44. Beurel E., *et al*. "The bidirectional relationship of depression and inflammation: double trouble". *Neuron* 107.2 (2020): 234-256.

45. Haroon E., *et al*. "Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior". *Neuropsychopharmacology* 37.1 (2011): 137-162.

46. Derry HM., *et al*. "Sex differences in depression: does inflammation play a role?". *Current Psychiatry Reports* 17.10 (2015).

47. Frodl T., *et al*. "Reduced expression of glucocorticoid-inducible genes gilz and sgk-1: high il-6 levels are associated with reduced hippocampal volumes in major depressive disorder". *Translational Psychiatry* 2.3 (2012): e88.

48. He L., *et al*. "Nrf2 regulates the arginase 1+ microglia phenotype through the initiation of trem2 transcription, ameliorating depression-like behavior in mice". *Translational Psychiatry* 12.1 (2022).

49. Hashimoto K. "Essential role of keap1-nrf2 signaling in mood disorders: overview and future perspective". *Frontiers in Pharmacology* 9 (2018).

50. Nakayama T., *et al*. "Seasonal changes in nrf2 antioxidant pathway regulates winter depression-like behavior". *Proceedings of the National Academy of Sciences* 117.17 (2020): 9594-9603.

51. Mellon S., *et al*. "Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment". *Translational Psychiatry* 6.5 (2016): e821-e821.

52. Duman RS., *et al*. "Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants". *Nature Medicine* 22.3 (2016): 238-249.

53. Koga Y., *et al*. "Tcf7l2: a potential key regulator of antidepressant effects on hippocampal astrocytes in depression model mice" (2023).

54. Felger J., *et al*. "Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue". *Psychological Medicine* 42.8 (2011): 1591-1603.

55. Apazoglou K., *et al*. "Antidepressive effects of targeting elk-1 signal transduction". *Nature Medicine* 24.5 (2018): 591-597.

56. Zhang J., *et al*. "Brain-derived neurotrophic factor (bdnf)-trkb signaling in inflammation-related depression and potential therapeutic targets". *Current Neuropharmacology* 14.7 (2016): 721-731.

57. Yang T., *et al*. "The role of bdnf on neural plasticity in depression". *Frontiers in Cellular Neuroscience* 14 (2020).

58. Lee BH and Kim YK. "The roles of bdnf in the pathophysiology of major depression and in antidepressant treatment". *Psychiatry Investigation* 7.4 (2010): 231.

59. Bahí A., *et al*. "Selective lentiviral-mediated suppression of microrna124a in the hippocampus evokes antidepressants-like effects in rats". *Psychoneuroendocrinology* 46 (2014): 78-87.

60. Penner-Goeke S and Binder E. "Epigenetics and depression". *Dialogues in Clinical Neuroscience* 21.4 (2019): 397-405.

Volume 17 Issue 2 February 2025